GAVI’S ENGAGEMENT IN POLIO ERADICATION

BOARD MEETING
Michael F Thomas, Stephen Sosler
6-7 June 2018, Geneva, Switzerland

Reach every child
www.gavi.org
Gavi’s involvement in polio eradication

• **July 2005:** Board decision to provide time-limited support for mOPV stockpile

• **November 2013:** Board decision to support IPV introduction with policy waivers

  **Dedicated funding:**
  - US$ 430 million provided by GPEI donors (BMGF, DFID and Norway) for the period 2013-2019

  **Policy exceptions:**
  - Co-financing
  - Eligibility
  - Transition policy

• **June 2017:** Board decision to continue IPV support through 2020 under same policy and funding conditions

• **June 2018:** Board to decide whether to support IPV through 2020 with core Gavi resources

• **December 2018:** Final Board decision on VIS investment case, including potential IPV support post-2020
Current polio situation and recent developments

Eradication progress
- 2018: 10 cases, 3 endemic countries
- Global certification no earlier than Q2 2021

IPV supply and price
- Improved supply in 2018, but remains fragile through 2020
- New vaccine tender – price increase of 60% - 140% for period 2019-2022*

SAGE recommendations
- 1 full or 2 fractional doses
- Catch-up vaccination of missed birth cohorts
- Move to 2-dose schedule

wP Hexavalent
- Progress made by some manufacturers on Hexavalent development
- Future Hexavalent scenarios to be incorporated into the VIS investment case

* Across 1 dose, 5 dose and 10 dose presentations
IPV support post-2020 (VIS)

**Primary considerations**
- Global public good – Insurance policy
- Alignment with SAGE recommendations
- Balancing risk appetite and costs

**Funding levers**
- **Country inclusion, eligibility**
  - 70 countries (status quo)
  - Tailored based on risk
  - Standard eligibility + transition policy
- **Country funding level**
  - Fully funded (status quo);
  - Tailored based on risk
  - Standard co-financing policy
- **Funding duration**
  - 10 yrs from bOPV removal
  - Tailored based on risk
  - Standard eligibility + transition policy
  - Until certification

**wP Hexavalent**
- Primary series (i.e. pentavalent)

**Programme factors**
- **Year of certification**: 2021
- **Supply**: Sufficient for 2 dose schedule
- **Dosing, vax schedule**: 2 full or fractional doses
- **Duration of use**: 10 years
- **Price**: WAP informed by recent tender
IPV support post 2020 (VIS): trade-off between risks and cost

Risk of IPV programme discontinuation

Gavi’s level of funding

LOW

HIGH

FOR GUIDANCE

Standard policies

Tailored approach

Status quo

Board meeting
6-7 June 2018
IPV support post 2020 (VIS): illustrative scenarios

**Estimated costs to Gavi**
*(in US$ millions)*

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Description</th>
<th>2021-2025</th>
<th>2026-2032</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Standard policies</strong></td>
<td>• Apply standard co-financing and eligibility policies</td>
<td>650</td>
<td>450</td>
<td>1,100</td>
</tr>
<tr>
<td></td>
<td>• Waive co-financing and eligibility policies for polio endemic, low income and preparatory transition countries</td>
<td>800</td>
<td>800</td>
<td>1,600</td>
</tr>
<tr>
<td></td>
<td>• Tailored co-financing for accelerated and fully self-financing countries</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Tailored approach</strong></td>
<td>• Maintain current exceptional waivers on co-financing and eligibility</td>
<td>900</td>
<td>1,200</td>
<td>2,100</td>
</tr>
<tr>
<td></td>
<td>• Fully finance 70 countries</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Status quo</strong></td>
<td>• Apply standard co-financing and eligibility policies</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Board meeting
6-7 June 2018
Broader engagement in polio eradication: *Polio transition*

<table>
<thead>
<tr>
<th>Risk level</th>
<th>Countries</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Endemic</strong></td>
<td>Afghanistan, Nigeria, Pakistan</td>
</tr>
<tr>
<td><strong>Very High</strong></td>
<td>Chad, Somalia, South Sudan</td>
</tr>
<tr>
<td><strong>High</strong></td>
<td>DR Congo, Ethiopia, Sudan</td>
</tr>
<tr>
<td><strong>Medium</strong></td>
<td>Angola, Cameroon</td>
</tr>
<tr>
<td><strong>Low</strong></td>
<td>Bangladesh, India, Indonesia, Myanmar, Nepal, all low probability</td>
</tr>
</tbody>
</table>

- Limited risk to Gavi in most countries
- Six fragile countries considered high-risk
- JAs increasingly being leveraged to determine immunisation-critical functions and capacities for time-limited bridging support
Broader engagement in polio eradication: *Post Certification*

**Post-Certification Strategy (PCS) developed**

**WHO draft strategic action plan presented to WHA**

### Essential polio functions

<table>
<thead>
<tr>
<th>Function</th>
<th>Part of current activities</th>
<th>Comparative advantage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strengthen immunization systems</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Ensure availability of affordable IPV</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Strengthened VPD surveillance and lab capacity</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Support for vaccine stockpiles (IPV and mOPVs)</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Strategies for sustained IPV use and financing</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Polio surveillance – AFP and environmental</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Containment of polioviruses</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polio outbreak preparedness, detection and response</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*FOR GUIDANCE*

Board meeting
6-7 June 2018
PPC recommendation to support IPV for 2019-2020

• POB request primarily a consequence of the extension of the polio eradication timelines

• Global supply constraints have resulted in underspend (2013-2018) and additional costs for vaccination of missed cohorts 2019-2020

Projected cost 2019-2020
Secured IPV donor funds available

<table>
<thead>
<tr>
<th></th>
<th>US$ 300 million</th>
<th>US$ 100 million</th>
</tr>
</thead>
<tbody>
<tr>
<td>Projected cost 2019-2020</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secured IPV donor funds available</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Estimated incremental cost = US$ 200 million
Recommendation

The Gavi Alliance Programme and Policy Committee recommends to the Gavi Alliance Board that it:

**Approve** the use of core resources for Gavi’s support for inactivated poliovirus vaccine (IPV) for the period 2019-2020, noting that the financial implications associated with this approval are expected to be approximately US$ 200 million.
THANK YOU